Abstracts

1056 – Some Barriers Persist, But State AIDS Drug Assistance Programs’ Challenges Ease Overall: 2017-2023 

Background AIDS Drug Assistance Programs (ADAPs) provide access to antiretroviral therapy for people with HIV with low incomes. Longitudinal trends in the challenges that ADAPs navigate have not been evaluated. Given recent policy shifts, such as the end of Medicaid continuous coverage, rising prescription drug and insurance costs, and federal funding uncertainty, we examined trends…

1070 – Preferences for Biomedical HIV Prevention Services of Alcohol-Venue Patrons/Workers in East Africa

Background Alcohol-serving venues are high-risk sites for HIV transmission in East Africa. However, the preferences of venue patrons and workers for biomedical HIV prevention services are unknown. Methods The OPAL trial (NCT05862857) recruited adults (age ≥18) at alcohol-serving venues in 8 rural communities in Kenya and Uganda (4/country) from 2023-25. Enrolled adults (n=7,744) completed clinic-based…

679 – Triglycerides to Glucose Ratio as a Predictor of Incident Hypertension in People With HIV

Background People with HIV (PWH) have an increased risk of hypertension (HTN), partly related to metabolic disturbances. The Triglycerides-glucose (TyG) index, a surrogate marker of insulin resistance and hepatic steatosis, has been associated with cardiovascular outcomes in the general population. Still, its role in predicting incident HTN in PWH remains unclear. Methods We conducted a…

697 – Tirzepatide Use in People With HIV Shows Effectiveness for Weight Loss and Diabetes Control

Background There is limited real-world evidence about the effectiveness of tirzepatide, a newer dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 receptor agonist (GLP-1RA), among people with HIV (PWH) in routine clinical care. We investigated changes in body weight and diabetes control in PWH starting therapy with tirzepatide while in care. Methods We examined…

704 – Cellular Senescence Impacts Both the Innate and Adaptive Immune System in Frail Men With HIV

Background Antiretroviral therapy (ART) has led to longer lifespans but an increased burden of age-associated conditions and frailty in people living with HIV (PLWH). Emerging evidence suggests that chronic inflammation and immune cell dysregulation contribute to frailty pathogenesis. The aim of this study was to examine the relationship between cellular immunosenescence and frailty in men with…

453 – MASH and the Progression of Cognitive Decline in Older People With HIV: A Prospective Study

Background Metabolic dysfunction-associated steatohepatitis (MASH), defined as steatosis with hepatocellular ballooning and lobular inflammation, is more common in people with HIV (PWH) and linked to systemic inflammation and extrahepatic complications, including cognitive impairment. We previously showed cross-sectional associations between MASH and poorer cognitive performance in older PWH. Here, we examined whether MASH predicts accelerated cognitive decline in…

259 – IL-6 Inhibits T-Cell Lineage Commitment of HSPCs During Pathogenic Retroviral Infection

Background Pathogenic retroviral infection, such as HIV/simian immunodeficiency virus (SIV), causes T cell lymphopenia. A fraction of people living with HIV, known as immunological nonresponders (INRs), present highly reduced thymic output despite complete viral suppression under therapy. The thymus, responsible for T cell regeneration, lacks autonomy in its ability to self-renew T cell committed progenitors,…

320 – Prior Immunity Continues to Protect Against Severe Mpox in 2025 Despite Time Since Vaccination

Background As the multinational mpox outbreak continues, ongoing transmission persists in the U.S. with recurrent clusters reported in 2025. Although vaccination and prior infection were associated with reduced severity early in the outbreak, the durability of this protection against severe disease remains uncertain. We evaluated disease severity among mpox cases diagnosed in 2025, focusing on…

539 – Long-Term Effectiveness of Lenacapavir in Heavily Treatment-Experienced People With HIV-1 in the US

Background Lenacapavir (LEN) is a first-in-class capsid inhibitor indicated for the treatment of HIV-1 in heavily treatment-experienced (HTE) adults in combination with other antiretrovirals (ARVs) and for HIV-1 prevention. We describe real-world effectiveness of LEN across 18 months (M) in a US-based cohort and optimized background regimen (OBR) patterns pre- and post-LEN.  Methods We retrospectively examined…